DR info

臨床試験数 : 10 / 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 9

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

AT132
   Audentes Therapeutics Inc.
      2018   Phase 1;Phase 2   EUCTR2017-000876-27-FR   France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-000876-27-DE   Canada;France;Germany;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2017-000876-27-GB   France;Germany;United Kingdom;United States;
ApoTamox
   James Dowling
      2020   Phase 1/Phase 2   NCT04915846   Canada;United Kingdom;United States;
DYN101
   Dynacure
      2021   Phase 1/Phase 2   NCT04743557   France;Germany;
      2020   Phase 1/Phase 2   NCT04033159   Belgium;Denmark;France;Germany;Netherlands;United Kingdom;United States;
      -   Phase 1;Phase 2   EUCTR2020-004608-32-DE   France;Germany;Netherlands;Spain;
L-Tyrosine
   Hadassah Medical Organization
      2014   Phase 2   NCT02035501   Israel;
N-acetylcysteine
   National Institute of Nursing Research (NINR)
      2015   Phase 1/Phase 2   NCT02362425   United States;
RAAV8-Des-hMTM1
   Audentes Therapeutics Inc.
      2018   Phase 1;Phase 2   EUCTR2017-000876-27-FR   France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-000876-27-DE   Canada;France;Germany;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2017-000876-27-GB   France;Germany;United Kingdom;United States;
SALBUTAMOL SULFATE
   Västra götalandsregionen
      2020   Phase 4   EUCTR2019-001147-51-SE   Sweden;
Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet
   Vastra Gotaland Region
      2021   -   NCT05099107   Sweden;
Salbutamol Only Product in Oral Dose Form
   Vastra Gotaland Region
      2021   -   NCT05099107   Sweden;
Ventoline oral solution 0,4mg/ml
   Västra götalandsregionen
      2020   Phase 4   EUCTR2019-001147-51-SE   Sweden;
Ventoline tablet
   Västra götalandsregionen
      2020   Phase 4   EUCTR2019-001147-51-SE   Sweden;